CDH Investments, Leadyond Capital Lead $39M Series B In Drug Discovery Firm HitGen

Login to View

Chinese alternative asset fund manager CDH Investments and Beijing-based Leadyond Capital have led a RMB250 million (US$39 million) series B round in Chengdu-based drug discovery firm HitGen, according to HitGen’s announcement.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in